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OBJECTIVE
In the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, ∼4 years
of intensive versus standard glycemic control in participants with type 2 diabetes
and other cardiovascular risk factors had a neutral effect on the composite car-
diovascular outcome, increased cardiovascular and total mortality, and reduced
nonfatal myocardial infarction. Effects of the intervention during prolonged
follow-up were analyzed.
RESEARCH DESIGN AND METHODS
All surviving ACCORD participants were invited to participate in the ACCORD
Follow-on (ACCORDION) study, during which participants were treated according
to their health care provider’s judgment. Cardiovascular and other health-related
outcomes were prospectively collected and analyzed using an intention-to-treat
approach according to the group to which participants were originally allocated.
RESULTS
A total of 8,601 people, representing 98% of those who did not suffer a primary
outcome or death during the ACCORD trial, were monitored for a median of
8.8 years and a mean of 7.7 years from randomization. Intensive glucose lowering
for a mean of 3.7 years had a neutral long-term effect on the primary composite
outcome (nonfatal myocardial infarction, nonfatal stroke, or cardiovascular
death), death from any cause, and an expanded composite outcome that included
all-cause death. Moreover, the risk of cardiovascular mortality noted during the
active phase (hazard ratio 1.49; 95% CI 1.19, 1.87; P < 0.0001) decreased (HR 1.20;
95% CI 1.03, 1.39; P = 0.02).
CONCLUSIONS
In high-risk people with type 2 diabetes monitored for 9 years, a mean of 3.7 years
of intensive glycemic control had a neutral effect on death and nonfatal cardio-
vascular events but increased cardiovascular-related death.
Type 2 diabetes is a strong risk factor for cardiovascular outcomes, and the incidence
of these outcomes rises with the degree of hyperglycemia (1). These clear relation-
ships support the hypothesis that glucose lowering may reduce these outcomes.
However, large randomized controlled trials have yielded mixed findings with re-
spect to the cardiovascular effects of glucose lowering. Four of these trials explicitly
tested the effect of intensive versus standard glucose lowering on cardiovascular
outcomes in people with type 2 diabetes (2–5). A meta-analysis of these four trials
suggested a beneficial or neutral effect on one ormore cardiovascular outcomes (6).
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However, one of these, the Action to
Control Cardiovascular Risk in Diabetes
(ACCORD) trial reported both increased
total and cardiovascular mortality and
reduced nonfatal myocardial infarction
in the intensive glucose-lowering group
during a mean follow-up period of
3.7 years (2). The reasons for these dis-
crepant findings remain unknown de-
spite many analyses. Also not known is
whether the effect on mortality or
myocardial infarctions was sustained
or limited by time. This uncertainty
was addressed by the ACCORD Follow-
on (ACCORDION) study, which consented
and monitored ACCORD participants for
up to 7 years after the intensive glycemic
intervention was stopped.
RESEARCH DESIGN AND METHODS
The design of the ACCORD trial and the
effect of intensive versus standard glucose-
lowering approaches on cardiovas-
cular outcomes have been previously
reported (2,7,8). Briefly, ACCORD enrolled
10,251 people whose mean age was
62 years, who had type 2 diabetes for a
median duration of 10 years with a
mean glycated hemoglobin (HbA1c) level
of 8.3%, and who had previous cardio-
vascular disease or cardiovascular dis-
ease risk factors. Participants in 77 sites
in the U.S. and Canada were randomly
assigned to intensive glucose-lowering
approaches targeting a glycated hemo-
globin level ,6% or to standard glucose-
lowering approaches targeting a level of
7–7.9%. Participants in both groups re-
ceived education and lifestyle advice re-
garding diabetesmanagement andwere
provided with glucose-lowering drugs at
no cost from a common formulary.
Achieved levels of glycated hemoglobin,
adverse effects of glucose-lowering
drugs, and rates of hypoglycemia were
recorded regularly throughout the trial,
and glucose-lowering therapies were
adjusted according to each participant’s
randomly assigned treatment group
and glycemic response to therapy. At
the time of allocation to the glycemic
strategy, ;4,733 ACCORD participants
(54%) were also enrolled in a blood
pressure trial and randomized to inten-
sive versus standard blood pressure
lowering (9). The remaining 5,518 (46%)
were enrolled in a lipid trial comprising
LDL lowering with a statin plus fenofibrate
or placebo (10). Details regarding the
findings of these trials have been reported
separately (2,7–10).
ACCORD participants were recruited
between June 2001 and October 2005,
managed according to their allocated
strategy, and monitored for occurrence
of cardiovascular and other health out-
comes. The active glycemic treatment
period ended on 5 February 2008
after amean follow-up period of 3.7 years,
when the National Heart, Lung, and
Blood Institute accepted the inde-
pendent Data and Safety Monitoring
Board’s recommendation to stop the
glycemia trial because of excess mortal-
ity in the intensive glucose-lowering
group. Subsequently, all participants
were managed according to the stan-
dard glucose-lowering approach and
monitored for an additional 17 months
until the active lipid and active blood
pressure treatment periods ended.
All surviving ACCORD participants
from participating sites who could be
contacted were subsequently offered
the opportunity to participate in the
ACCORDION study, during which car-
diovascular and other health-related
outcomes and measurements were
collected and analyzed according to
the group to which participants were
originally allocated. No active thera-
pies were provided by the study during
this follow-up period. All participants
gave written, informed consent to par-
ticipate in ACCORDION.
Outcome Ascertainment
The glycemic portion of the ACCORDION
study was designed to assess the effect
of 3.7 years of exposure to the ACCORD
intensive versus the standard glycemic
glucose-lowering approach on the long-
term incidence of cardiovascular out-
comes. Consenting participants were
seen or called by 72 sites in the U.S.
and Canada on up to seven occasions
between May 2011 (;1.5 years after
the conclusion of the ACCORD trial) and
October 2014. During four telephone and
three clinic visits, the occurrence of car-
diovascular outcomes, deaths, dialysis, all
hospitalizations, severe hypoglycemia,
medication usage, and related informa-
tion was ascertained. Documentation
supporting the diagnosis ofmyocardial in-
farction, unstable angina, strokes, and
deaths was sought and verified by the
site. Weight, height, waist circumference,
blood pressure, pulse, and a neuropathy
examination were conducted at each
clinic visit. Glycated hemoglobin, a lipid
profile, serum creatinine, alanine amino-
transferase level, and a spot urine albumin-
to-creatinine ratiowere centrallymeasured
at the first and third visits, during which
an electrocardiogram and data con-
cerning health-related quality of life
were also collected. Deaths in the U.S.
were also ascertained using the Na-
tional Death Index.
As in ACCORD, the primary outcome
was the composite of cardiovascular
death, nonfatal myocardial infarction,
or nonfatal stroke. Prespecified second-
ary outcomes included an expanded
composite outcome comprising the pri-
mary end point, any revascularization,
or hospitalization for heart failure; a
composite outcome comprising the
primary end point or death from any
cause; a coronary heart disease com-
posite comprising fatal or nonfatal myo-
cardial infarction, death occurring
unexpectedly or after a cardiovascular
procedure or noncardiovascular sur-
gery, or unstable angina; nonfatal myo-
cardial infarction; stroke; nonfatal
stroke; all-cause mortality; cardiovascu-
lar mortality; and heart failure death or
hospitalization.
All of the reported cardiovascular
outcomes during the ACCORD trial
were adjudicated by a masked, inde-
pendent committee. Conversely, in
light of evidence showing that adjudi-
cation does not materially affect the
estimate of the effect size in random-
ized trials (11,12), only a randomly se-
lected 10% of the reported outcomes
were similarly adjudicated during the
ACCORDION follow-up phase (to en-
sure quality control). Analyses in
ACCORDION were conducted on all of
the cardiovascular outcomes that oc-
curred after randomization and that
were reported by the sites during the
active or follow-up period, regardless
of the final adjudication status. Out-
come definitions were identical to
those used in ACCORD and are avail-
able online (13).
Statistical Analysis
Statistical analyses were undertaken by
the ACCORD Coordinating Centre using
SAS 9.4 software (SAS Institute Inc.,
Cary, NC), according to a prespecified
plan that was finalized before any anal-
yses began. A nominal level of significance
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of P , 0.05 was used for all analyses
without adjustment for multiple testing.
Baseline characteristics of people ran-
domized to the ACCORD trial and the
subset that consented to subsequent
passive follow-up were summarized us-
ing means, SDs, and percentages. The
use of glucose-lowering drugs was sum-
marized as the number of participants
who reported taking medication at the
last contact with the participant. The ef-
fect of the interventions on glycated
hemoglobin levels during the active
treatment phase and subsequent follow-
up was estimated by calculating the
median glycated hemoglobin at each
follow-up visit by treatment group in
monthly intervals from randomization.
Follow-up for each patient was defined
as the time from randomization until an
outcome occurred or the last date for
which the participant’s health status
was available.
The incidence rate and number of
participants at risk for events dur-
ing follow-up was determined using
Kaplan-Meier estimates. Cox propor-
tional hazards regression analyses
were used to estimate the long-term
effect of allocation to intensive versus
standard glycemic control on the pri-
mary and secondary outcomes using a
x2 statistic from a likelihood ratio test
obtained from proportional hazards
models with and without the term for
intervention arm. Hazard ratios and
95% CIs were calculated using models
that included independent variables
that were prespecified in prior ACCORD
analyses. Primary outcome model co-
variates included 1) assignment to the
blood pressure or lipid trials; 2) assign-
ment to the intensive versus standard
blood pressure intervention; 3) assign-
ment to fibrate versus placebo; 4) the
presence or absence of previous car-
diovascular disease; and 5) the clinical
center network within which the partic-
ipant was monitored. Secondary out-
comes were analyzed using the same
list of covariates, with the exception
of clinical center networks, because of
the reduced number of anticipated
events. All outcomes were censored
on the date of the last available infor-
mation, and all comparisons of interven-
tion groups were performed according
to the intention-to-treat principle. The
consistency of the effect of the study
groupassignmenton theprimaryoutcome
and mortality within prespecified sub-
groups (previous cardiovascular event
vs. none, men vs. women, randomiza-
tion age ,65 or $65 years, randomi-
zation glycated hemoglobin #8% or
.8%, white vs. nonwhite, and blood
pressure trial vs. lipid trial) was as-
sessed with the use of statistical tests
of interactions between the treatment
effect and the subgroup within the Cox
models.
RESULTS
Supplementary Figure 1 displays partic-
ipant follow-up during and after the
ACCORD trial. Ninety percent (n = 8,601) of
these living individuals, representing
98% of the 8,777 individuals without a
primary outcome event during the ac-
tive phase of the ACCORD trial, con-
sented to further, posttrial follow-up.
Of 10,251 randomized ACCORD partici-
pants, 9,533 (93%) were known to be
alive at the end of the full ACCORD trial
(when both the lipid and blood pressure
interventions were discontinued), and
8,777 remained free of a myocardial in-
farction of stroke (i.e., the first occur-
rence of a nonfatal component of the
primary outcome) at that time. Partici-
pants who agreed to ongoing follow-up
were younger and at the time of ran-
domization had lower serum creatinine
and LDL levels, had a lower prevalence of
smoking and prior cardiovascular events,
were less likely to be on insulin, andwere
more likely to be taking metformin, sta-
tins, and aspirin than the 1,650 ACCORD
participants who had died or did not
agree to further follow-up (Table 1).
The between-group difference in gly-
cated hemoglobin (Supplementary Fig. 2)
Table 1—Baseline characteristics according to follow-up
Consent to post-ACCORD follow-up
Baseline characteristic No (n = 1,650) Yes (n = 8,601) P value
Females, n (%) 630 (38.2) 3,322 (38.6) 0.74
Age (years) 63.7 (7.7) 62.0 (6.6) 0.03
Duration of diabetes (years) 11.2 (8.3) 10.8 (7.7) 0.14
BMI (kg/m2) 32.2 (5.5) 32.3 (5.5) 0.68
Waist circumference (cm) 107.3 (14.2) 106.7 (13.8) 0.09
Blood pressure (mmHg)
Systolic 138 (18) 136(17) ,0.001
Diastolic 75 (11) 75 (11) 0.40
Prior cardiovascular disease, n (%) 748 (45.3) 2,861 (33.3) ,0.001
Current smoker, n (%) 292 (17.7) 1,137 (13.2) ,0.001
Postsecondary education, n (%) 844 (57.2) 5,175 (60.2) ,0.001
Ethnicity, n (%)
White 955 (57.9) 5,438 (63.2)
Black 414 (25.1) 1,539 (17.9)
Hispanic 136 (8.2) 601 (7.0)
Other 145 (8.8) 1,023 (11.9) ,0.001
Key medications, n (%)
Insulin 628 (38.1) 2,953 (34.3) 0.004
Metformin 884 (53.6) 5,251 (61.1) ,0.001
Sulfonylurea 771 (46.7) 4,365 (50.7) 0.003
Thiazolidinedione 285 (17.3) 1,697 (19.7) 0.02
Statin 937 (56.8) 5,427 (63.1) ,0.001
ACE inhibitor or ARB 1,102 (61.9) 5,840 (67.9) 0.38
Acetylsalicylic acid 836 (50.7) 4,743 (55.1) ,0.001
Laboratory values
HbA1c (%) 8.4 (1.2) 8.3 (1.0) ,0.001
Serum creatinine (mg/dL) 0.95 (0.26) 0.90 (0.22) ,0.001
eGFR (mL/min) 90.6 (33.4) 91.1 (25.8) 0.54
Urine albumin-to-creatinine ratio 18.3 (8.0, 72.0) 12.9 (6.7, 39.8) ,0.001
Cholesterol (mg/dL) 186.1 (43.7) 182.8 (41.5) 0.005
LDL 108.1 (35.7) 104.3 (33.5) ,0.001
HDL 41.8 (12.4) 41.9 (11.5) 0.68
Triglycerides (mg/dL) 154 (102, 226) 155 (107, 229) 0.76
Data are n (%), mean (SD), or median (interquartile range). ARB, angiotensin receptor blocker;
eGFR, estimated glomerular filtration rate.
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achieved during a mean active treat-
ment period of 3.7 years was clearly
smaller but persisted well after transi-
tion of all participants to the standard
glycemic treatment strategy. Thus, a
mean of 1.2 years after transition (i.e.,
when the ACCORD trial ended), the
mean (SD) glycated hemoglobin level
was 7.4% (1.2%) in the intensive group
and 7.8% (1.3%) in the standard group
(P , 0.001), and at the end of the
ACCORDION follow-up, these levels
were 7.8% (1.4%) and8.0% (1.4%), respec-
tively (P = 0.005). This HbA1c difference
persisted during the ACCORDION follow-
up period despite similar reported glucose-
lowering regimens (Supplementary
Table 1) and similar weights of 91.8
(20.4) kg and 91.2 (20.4) kg (P = 0.4)
in people who had been allocated to
the intensive and standard groups,
respectively.
During the ACCORDION phase of the
study, there were similar rates of severe
hypoglycemia requiring medical assis-
tance or any severe hypoglycemia in
each allocated group (Supplementary
Table 2).
The incidence of reported clinical
outcomes and the hazard of allocation
to the intensive versus the standard
glucose-lowering regimen during the
ACCORD trial and the full ACCORDION
median follow-up period of 8.8 years
are shown in Fig. 1 and listed in Table 2.
Allocation to an intensive glucose-
lowering regimen for a mean of 3.7 years
had a neutral long-term effect on the
first occurrence of the primary com-
posite outcome comprising nonfatal
myocardial infarction, nonfatal stroke,
or cardiovascular death; death from
any cause; an expanded composite of
nonfatal myocardial infarction, nonfa-
tal stroke, or any death; a composite
of fatal coronary heart disease, nonfa-
tal myocardial infarction, or unstable
angina; and heart failure hospitaliza-
tions. Conversely, the increase in death
from cardiovascular causes that was
noted at the end of the active treat-
ment period persisted. However, as a
result of similar rates after the inter-
vention, the hazard ratio was attenu-
ated to 1.20 (95% CI 1.03, 1.39; P =
0.02). Product-limit estimates of time
to event for the primary outcome, death
(Fig. 2), and for the three components of
the primary outcome (Fig. 3) suggested
that any differences in incidence were
confined to the active treatment period.
No differences in the long-term effect of
the intervention on the primary out-
come or mortality were noted for prede-
fined subgroups (Supplementary Figs. 3
and 4).
CONCLUSIONS
Intensive glycemic control may have
long-term effects on serious health out-
comes in people with type 2 diabetes.
Such “legacy” effects may be beneficial
or harmful and may emerge, be attenu-
ated, or become magnified with time.
These data from the long-term follow-up
of the ACCORD trial show that intensive
glycemic control for a median of 3.7 years
had a prolonged effect on HbA1c levels,
possibly due to some effect on b-cell
function (14). At the same time, it had a
neutral effect on the primary cardiovas-
cular composite outcome of nonfatal
myocardial infarction, nonfatal stroke,
or cardiovascular death during a me-
dian follow-up period of 8.8 years. It
also had a neutral effect on an ex-
panded composite outcome that in-
cluded death from any cause and the
individual outcomes of nonfatal myo-
cardial infarction, nonfatal stroke, and/or
congestive heart failure.
Intensive glycemic control had a neu-
tral long-term effect on all-cause mor-
tality during this 8.8-year period,
despite the higher mortality during the
3.7-year active phase of the ACCORD
trial. Scrutiny of the product-limit curves
(Fig. 2) and accrued data (Table 2) show
that this was apparently due to cluster-
ing of the excess of cardiovascular
deaths between 2 and 3 years after ran-
domization and subsequent attenuation
or reversal of this pattern. The reduction
in nonfatal myocardial infarction noted
during the active phase of the trial was
also attenuated over the entire follow-
up period.
The excess of cardiovascular-specific
mortality accompanying intensive ther-
apy that was noted during the active
phase of the trial remains unexplained
despite many analyses. Possible expla-
nations that have not been supported
include severe hypoglycemia (15);
weight gain (R.P. Byington, unpublished
analysis); the specific therapies used to
lower glucose, including insulin (16) or
other glucose-lowering drugs (unpub-
lished analysis); or the differential ef-
fects of intensive control in people
with underlying cardiac autonomic neu-
ropathy (17). The degree of glucose
lowering that was achieved in the inten-
sive group was also not responsible for
the mortality signal (18). Indeed, two
ACCORD analyses found that the excess
mortality in the intensive group was
most apparent in participants whose
HbA1c levels remained high despite allo-
cation to the intensive group and use of
therapeutic strategies seeking nearly
normal glucose levels (18,19). Other
Figure 1—Hazard of outcomes during ACCORD and ACCORD/ACCORDION. The event rates and
hazard ratios (HRs,C) with 95% CIs (horizontal lines) are shown for prespecified outcomes that
occurred from randomization until the end of the ACCORD trial and until the end of prolonged
follow-up comprising the ACCORD and ACCORDION phase. MI, myocardial infarction.
704 Nine-Year ACCORD Follow-up Diabetes Care Volume 39, May 2016
analyses have suggested that the excess
of mortality may have been due to a
harmful effect of the intervention in
subgroups of individuals with periph-
eral neuropathy, aspirin use, or HbA1c
$8.5% at baseline (20), or in the sub-
group with the highest discrepancy be-
tween baseline HbA1c and the HbA1c
levels that would be predicted from
fasting plasma glucose levels (due to
higher protein glycation, higher prandial
glucose levels, or other reasons) (21).
Finally, that the excess mortality during
ACCORD may have been a rare chance
occurrence has been suggested (22).
The absence of excess mortality in the
active phase of the three other trials of
intensive glucose control (6), the concom-
itant reduction in nonfatal myocardial in-
farction and various indices of ischemic
heart disease during this phase (6,23),
and attenuation of the mortality signal
during the full 9 years of follow-up pro-
vide some support for this possibility.
Figure 2—The Kaplan-Meier curves display the time to event for the primary outcome (A) and total mortality (B) during follow-up from random-
ization until the end of ACCORDION. The inset for each graph displays the same curve with a magnified y-axis. The numbers of individuals at risk are
shown for each time point.
Table 2—First occurrence of outcomes during different study phases
During ACCORD Post-ACCORD alone Full follow-up from randomization
Intensive
(n = 5,128)
Standard
(n = 5,123)
Intensive
(n = 4,270)
Standard
(n = 4,331)
Intensive
(n = 5,128)
Standard
(n = 5,123)
Outcome n % n % n % n % n % n %
Primary outcome 546 10.6 582 11.4 350 8.2 348 8.0 896 17.3 930 18.3
Death 391 7.6 327 6.4 589 13.8 651 15.0 980 19.1 978 19.1
Nonfatal MI 303 5.9 360 7.0 141 3.3 132 3.0 444 8.7 492 9.6
Nonfatal stroke 119 2.3 142 2.8 108 2.5 119 2.7 227 4.4 261 5.1
CVD 185 3.6 125 2.4 179 4.2 180 4.2 364 7.1 305 6.0
Primary outcome or death 722 14.1 753 14.7 685 16.0 719 16.6 1,407 27.4 1,472 28.7
Primary outcome, Revasc, CHF 1,210 23.6 1,269 24.8 490 11.5 523 12.1 1,700 33.2 1,792 35.0
Fatal CHD, MI, UA 606 11.8 647 12.6 292 6.8 314 7.3 898 17.5 961 18.8
Any stroke 128 2.5 150 2.9 114 2.7 124 2.9 242 4.7 274 5.4
CHF hospitalization 233 4.5 203 4.0 107 2.5 153 3.5 340 6.6 356 7.0
Causes of death
Fatal MI 29 7.4 14 4.3 11 1.9 7 1.1 40 4.1 21 2.2
Fatal stroke 8 2.1 8 2.5 5 0.9 5 0.8 13 1.3 13 1.3
Unexpected, presumed CVD 82 21.0 65 19.9 47 8.0 45 6.9 129 13.2 110 11.3
CHF 22 5.6 9 2.8 21 3.6 19 2.9 43 4.4 28 2.9
Documented arrhythmia 4 1.0 3 0.9 4 0.7 2 0.3 8 0.8 5 0.5
Other cardiovascular 40 10.2 26 8.0 91 15.5 102 15.7 131 13.4 128 13.1
Cancer 95 24.3 89 27.2 68 11.5 77 11.8 163 16.6 166 17.0
Non-CVD/noncancer 95 24.3 95 29.1 0 0.0 0 0.0 95 9.7 95 9.7
Other non-CVD or unknown 10 2.6 17 5.2 227 38.5 251 38.6 237 24.2 268 27.4
Uncertain* 6 1.5 1 0.3 115 19.5 143 22.0 121 12.4 144 14.7
CHD, coronary heart disease; CHF, congestive heart failure; CVD, cardiovascular death; MI, myocardial infarction; Revasc, revascularization; UA,
unstable angina. *Identified using the National Death Index.
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The 10- to 20-year effect of up to
6 years of intensive glycemic control on
cardiovascular outcomes has also been
reported in the three other large out-
comes trials of intensive glucose control.
In the UK Prospective Diabetes Study
(UKPDS), 10 years of active therapy
achieving a median HbA1c difference
of 0.9% reduced the 18-year incidence
of myocardial infarction by 15% and
death by 13% in people with newly di-
agnosed type 2 diabetes (24). Similarly,
6 years of active therapy achieving an
HbA1c difference of 1.5% reduced the
10-year incidence of cardiovascular
outcomes by 17% in male veterans
who participated in the Veterans Af-
fairs Diabetes Trial (VADT) (25). The Ac-
tion in Diabetes and Vascular Disease:
Preterax and Diamicron MR Controlled
Evaluation (ADVANCE) trial, with a lesser
glycemic difference, reported that 5
years of intensive glycemic control
had a neutral effect on cardiovascular
outcomes during 10 years of follow-up
(26). Two of these posttrial intention-
to-treat follow-up analyses reported a
neutral effect on mortality, and one
reported a reduction. A meta-analysis
of the odds ratios for death from
ACCORDION and these other three stud-
ies using a fixed-effects variance estimate
(27) with heterogeneity assessed using
the I2 statistic (28) (Supplementary
Table 3) yields an overall mortality
odds ratio of 0.98 (95% CI 0.92, 1.04).
Taken together, the findings of
ACCORDION demonstrate neither a
beneficial legacy effect of 3.7 years of
intensive glucose-lowering therapy on
cardiovascular end points nor a contin-
ued excess of all-cause mortality. The
unexplained 20% higher relative risk of
cardiovascular death in ACCORDION
corresponds to an absolute risk differ-
ence of ;0.13%/year or 1.3% over
10 years. When deciding on therapy for
an individual patient, these findings
need to be balanced against a neutral
effect on overall mortality and a large
reduction in eye disease in response to
intensive glucose lowering (29). These
findings suggest that for people with
type 2 diabetes and additional cardio-
vascular risk factors, the main benefits
of intensive glycemic control are non-
cardiovascular. They also support cur-
rent recommendations (30,31) to
tailor the degree of glucose control
to the overall health status of individual
patients, taking their overall frailty and
burden of other illnesses into account.
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Figure 3—The Kaplan-Meier curves display the time to event for the three components of the primary outcome, including nonfatal myocardial
infarction (MI) (A), nonfatal stroke (B), and cardiovascular (CV) death (C) during follow-up from randomization until the end of ACCORDION. The
inset displays the same curve with a magnified y-axis. The numbers of individuals at risk are shown for each time point.
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